<div class="white-sheet">
    <div class="content-slide">

<!-- Secondary scene 1 -->
    <div class="content secondary-scene">
        <!--<h1>Content</h1>-->
        

                <div class="title-bar red"></div>

                <div class="wrapper slide-2-6-3">

                    <div class="vertical-nav">
                        <ul>
                            <li class="active"></li>
                            <li></li>
                            <li></li>
                            <li></li>
                            <li></li>
                        </ul>
                    </div>

                    <div class="popups" style="position:absolute">
                        <div data-effect="fade" data-duration="1000" data-target="references1-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
                        <div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div> 
                    </div>

                    <div class="slide-title red">
                        New approaches in severe aplastic anaemia treatment
                    </div>


                    <div class="content-container">

                        <div class="content-left">
                            
                            <ul>
                                <li><span>The goal in severe aplastic anaemia is to find treatments with fewer side-effects than current options</span></li>
                                <li><span>Therapeutic agents currently being investigated for severe aplastic anaemia are:</span>
                                    <ul>
                                        <li><span>Eltrombopag: Phase II1,<sup>2</sup></span>
                                            <ul>
                                                <li><span>Oral thrombopoietin mimetic <sup>2</sup></span></li>
                                            </ul>
                                        </li>
                                        <li><span>Alemtuzumab: Phase III<sup>2,3</sup></span>
                                            <ul>
                                                <li><span>Humanised anti-CD52 IgG1 monoclonal antibody (immunosuppressive agent)<sup>2</sup></span></li>
                                            </ul>
                                        </li>
                                    </ul>
                                </li>
                            </ul>

                        </div>


                        <div class="content-right">

                            <div class="red-label">Structures of (A) alemtuzumab and (B) eltrombopag</div>
                            
                             <img src="media/images/slide_2-6-3/picture1.png" class="center-img" alt="">

                        </div>
                
                       

                    </div>

                </div>

                <div class="information-overlay overlay" style="font-size:12px;">

                    <header>New approaches in severe aplastic anaemia treatment</header>
                        
                    <ul>
                        <li><span>The National Heart Lung and Blood Institute (NHLBI) is conducting trials for alemtuzumab and daclizumab</span></li>
                        <li><span>Alemtuzumab is being investigated in Phase III trials as monotherapy for treatment-naïve, relapsed and refractory severe aplastic anaemia<sup>3</sup></span>
                            <ul>
                                <li><span>It is a humanised monoclonal antibody directed against CD52 antigen on the surface of mature T cells</span></li>
                                <li><span>Refractory patients: response rate: 37%; 3-year survival: 83%</span></li>
                                <li><span>Relapsed patients: response rate: 56%; 3-year survival: 86%</span></li>
                            </ul>
                        </li>
                        <li><span>Daclizumab is being investigated in Phase II trials for the treatment of moderate aplastic anaemia<sup>4</sup></span>
                            <ul>
                                <li><span>It acts by blocking the action of IL-2</span></li>
                            </ul>
                        </li>
                    </ul>

                </div>


                <div class="references1-overlay overlay">

                    <header>References</header>
                        
                    <ol>
                        <li class="navigateHref" data-navtarget="media/documents/ZhangC-2008-CurrOpinHematol-v15p307.pdf"><span>Olnes MJ <i>et al. N Eng J Med</i> 2012;367:11</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/ZhangC-2008-CurrOpinHematol-v15p307.pdf"><span>Marsh JWC & Kulasekararaj AG. <i>Blood</i> 2013;122:3561</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/ZhangC-2008-CurrOpinHematol-v15p307.pdf"><span>Scheinberg P <i>et al. Blood</i> 2012;119:345</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/ZhangC-2008-CurrOpinHematol-v15p307.pdf"><span>Sloand EM <i>et al. Haematologica</i> 2010;95:382</span></li>
                    </ol>

                </div>


          
    </div>
    <!-- End of secondary scene 1 -->
    <!-- Secondary scene 2 (Static Content) -->
    <div class="content secondary-scene">
         

                <div class="title-bar blue"></div>

                <div class="wrapper slide-2-6-3a">

                    <div class="vertical-nav">
                        <ul>
                            <li></li>
                            <li class="active"></li>
                            <li></li>
                            <li></li>
                            <li></li>
                        </ul>
                    </div>

                    <div class="popups" style="position:absolute">
                        <div data-effect="fade" data-duration="1000" data-target="references2-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>        
                    </div>

                    <div class="slide-title blue two-line">
                        Unmet needs in the treatment of severe aplastic<br /> anaemia
                    </div>


                    <div class="content-container">
                
                        <ul>
                            <li><span>Stem cell transplantation and IST are the current options for the treatment of aplastic anaemia<sup>1</sup></span>
                                <ul>
                                    <li><span>However, fewer than 30% of patients will have an HLA-matched sibling donor<sup>2</sup></span></li>
                                    <li><span>Transplant is associated with potentially life-threatening complications including GVHD<sup>2</sup></span></li>
                                </ul>
                            </li>
                            <li><span>Patients may relapse or become refractory to IST<sup>1</sup></span>
                                <ul>
                                    <li><span>A second course with rabbit ATG and CSA may be associated with variable response rates of 27–77% but this is still inferior to the responses seen in the relapsed setting<sup>3,4</sup></span></li>
                                    <li><span>Additional treatment options for refractory disease are limited</span></li>
                                </ul>
                            </li>
                            <li><span>Long-term supportive care may be associated with a significant transfusion burden<sup>5</sup></span>
                                <ul>
                                    <li><span>Repeated transfusion of blood products to maintain cell counts may lead to iron overload and damage to internal organs</span></li>
                                    <li><span>Alloimmunisation may limit transfusion efficacy after repeated use<sup>6</sup></span></li>
                                </ul>
                            </li>
                            <li><span>Disease progression to cytogenetic disorders such as MDS and leukemia<sup>7</sup> occurs at a rate of 10–20% per 10 years<sup>7,8</sup> in patients with severe aplastic anaemia</span></li>
                        </ul>       

                    </div>

                </div>


                <div class="references2-overlay overlay">

                    <header>References</header>
                        
                    <ol>
                        <li class="navigateHref" data-navtarget="media/documents/Pallister&Watson-2011-Haematology-v2p27-35.pdf"><span>Aplastic Anaemia Therapeutics – Pipeline Assessment and Market Forecasts to 2019.” Research and Markets, February 2012. http://www.researchandmarkets.com/reports/2114301/aplastic_anemia_therapeutics_pipeline.htm (accessed Oct 2013)</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/Pallister&Watson-2011-Haematology-v2p27-35.pdf"><span>Brodsky RA & Jones RJ. <i>Lancet</i> 2005;365:1647</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/Pallister&Watson-2011-Haematology-v2p27-35.pdf"><span>Di Bona E <i>et al. Br J Haematol</i> 1999;107:330</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/Pallister&Watson-2011-Haematology-v2p27-35.pdf"><span>Scheinberg P <i>et al. Br J Haematol</i> 2006;133:622</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/Pallister&Watson-2011-Haematology-v2p27-35.pdf"><span>Lee JW <i>et al. Blood</i> 2010;116:2448</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/Pallister&Watson-2011-Haematology-v2p27-35.pdf"><span>Dutch Blood Transfusion Guideline. 2011. http://www.sanquin.nl/repository/documenten/en/prod-en-dienst/287294/blood-transfusion-guideline.pdf (accessed January 2014)</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/Pallister&Watson-2011-Haematology-v2p27-35.pdf"><span>Scheinberg P <i>et al. Blood</i> 2012;120:1185</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/Pallister&Watson-2011-Haematology-v2p27-35.pdf"><span>Maciejewski JP & Selleri C. <i>Leukaemia & Lymphoma</i> 2004;45:433</span></li>
                    </ol>

                </div>

          
    </div>
    <!-- End of secondary scene 2 -->
    <!-- Secondary scene 3 (Static Content) -->
    <div class="content secondary-scene">
         

                <div class="title-bar blue"></div>

                <div class="wrapper slide-2-6-3b">

                    <div class="vertical-nav">
                        <ul>
                            <li></li>
                            <li></li>
                            <li class="active"></li>
                            <li></li>
                            <li></li>
                        </ul>
                    </div>

                    <div class="popups" style="position:absolute">
                        <div data-effect="fade" data-duration="1000" data-target="references2-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>        
                    </div>

                    <div class="slide-title blue two-line">
                        Investigational therapies in severe aplastic anaemia:<br /> 
                        developments in stem cell transplantation
                    </div>


                    <div class="content-container">
                
                        <ul>
                            <li><span>Alternative stem cell sources have been investigated intensively, because many patients lack a histocompatible unrelated donor for HSCT<sup>1</sup></span>
                                <ul>
                                    <li><span>Unrelated donor (UD) bone marrow HSCT results in higher rates of GVHD<sup>1–3</sup></span></li>
                                    <li><span>UD blood HSCT results in graft rejection, poor immune reconstitution and susceptibility to viral reactivations<sup>1,4,5</sup></span></li>
                                </ul>
                            </li>
                            <li><span>Methods to improve the feasibility of haploidentical donors for HSCT include:</span>
                                <ul>
                                    <li><span>Manipulation of the graft before infusion to reduce rates of GVHD<sup>6</sup></span>
                                        <ul>
                                            <li><span>Selective removal of T cells and repleting non-CD34+ cells<sup>6</sup></span></li>
                                        </ul>
                                    </li>
                                    <li><span>Post-transplant administration of high-dose cyclophosphamide (50 mg/kg/day)<sup>7</sup></span></li>
                                </ul>
                            </li>
                            <li><span>Evidence for the combination of haploidentical and umbilical cord blood cells is promising<sup>8</sup></span></li>
                        </ul>       

                    </div>

                </div>


                <div class="references2-overlay overlay">

                    <header>References</header>
                        
                    <ol>
                        <li><span>Scheinberg P. <i>Hematology Am Soc Hematol Educ Program</i> 2012;292</span></li>
                        <li><span>Passweg JR <i>et al. Bone Marrow Transplant</i> 2006;37:641</span></li>
                        <li><span>Perez-Albuerne <i>et al. Br J Haematol</i> 2008;141:216</span></li>
                        <li><span>Liu H-L <i>et al. Bone Marrow Transplantation</i> 2012;47:1186</span></li>
                        <li><span>Peffault de Latour R <i>et al. Biol Blood Marrow Transplant</i> 2011;17:78</span></li>
                        <li><span>Koh KN <i>et al. Br J Haematol</i> 2012;157:125</span></li>
                        <li><span>De Zern AE <i>et al. Bone Marrow Transplant</i> 2011;46:1012</span></li>
                        <li><span>Kwon M <i>et al. Biol Blood Marrow Transplant</i> 2013;19:143</span></li>
                    </ol>

                </div>

          
    </div>
    <!-- End of secondary scene 3 -->
    <!-- Secondary scene 4 (Static Content) -->
    <div class="content secondary-scene">
         

                <div class="title-bar blue"></div>

                <div class="wrapper slide-2-6-3c">

                    <div class="vertical-nav">
                        <ul>
                            <li></li>
                            <li></li>
                            <li></li>
                            <li class="active"></li>
                            <li></li>
                        </ul>
                    </div>

                    <div class="popups" style="position:absolute">
                        <div data-effect="fade" data-duration="1000" data-target="references2-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>        
                    </div>

                    <div class="slide-title blue two-line">
                        Ongoing investigator-led trials evaluating haematopoietic<br />
                         stem cell transplant in severe aplastic anaemia
                    </div>


                    <div class="content-container">
                
                        <table class="wide blue">
                            <tr>
                                <th>Title</th>
                                <th>Lead sponsor</th>
                                <th>Phase</th>
                                <th>Patients (n)</th>
                                <th>Primary completion</th>
                                <th>End date</th>
                                <th>NCT number</th>
                            </tr>

                            <tr class="odd">
                                <td>Allogeneic HSCT transplant for SAA and other bone marrow failure syndromes using G-CSF mobilised CD34+ selected haematopoietic precursor cells co-infused with a reduced dose of non-mobilised donor T cells</td>
                                <td>National Heart Lung and Blood Institute (NHLBI)</td>
                                <td>II</td>
                                <td>110</td>
                                <td>June 2014</td>
                                <td>June 2015</td>
                                <td>NCT01174108</td>
                            </tr>

                            <tr>
                                <td>Co-infusion of umbilical cord and haploidentical CD34+ cells following non-myeloablative conditioning as treatment for SAA and MDS associated with severe neutropenia refractory to immunosuppressive therapy</td>
                                <td>NHLBI</td>
                                <td>II</td>
                                <td>100</td>
                                <td>December 2014</td>
                                <td>December 2015</td>
                                <td>NCT00604201</td>
                            </tr>

                            <tr class="odd">
                                <td>A prospective phase II study to evaluate cord blood transplantation in inherited or acquired SAA refractory or in relapse after IST</td>
                                <td>Assistance Publique – Hôpitaux de Paris</td>
                                <td>II</td>
                                <td>26</td>
                                <td>May 2014</td>
                                <td>May 2014</td>
                                <td>NCT01343953</td>
                            </tr>

                            <tr>
                                <td>A phase II trial of myeloablative conditioning and transplantation of HLA-matched, partially HLA-mismatched, HLA-halpoidentical or matched unrelated (MUD) bone marrow for patients with refractory SAA</td>
                                <td>Sidney Kimmel Comprehensive Cancer Centre</td>
                                <td>II</td>
                                <td>25</td>
                                <td>June 2014</td>
                                <td>June 2015</td>
                                <td>NCT01383434</td>
                            </tr>

                            <tr class="odd">
                                <td>Allogeneic stem cell transplantation for patients with SAA using MUDs and mismatched related donors</td>
                                <td>Mayo Clinic</td>
                                <td>II/III</td>
                                <td>24</td>
                                <td>February 2014</td>
                                <td>February 2016</td>
                                <td>NCT00578266</td>
                            </tr>
                        </table>     

                    </div>

                </div>


                <div class="references2-overlay overlay">

                    <header>References</header>
                        
                    <ol>
   
                    </ol>

                </div>

          
    </div>
    <!-- End of secondary scene 4 -->
    <!-- Secondary scene 5 (Static Content) -->
    <div class="content secondary-scene">
         

                <div class="title-bar blue"></div>

                <div class="wrapper slide-2-6-1a">

                    <div class="vertical-nav">
                        <ul>
                            <li></li>
                            <li></li>
                            <li></li>
                            <li></li>
                            <li class="active"></li>
                        </ul>
                    </div>

                    <div class="popups" style="position:absolute">
                        <div data-effect="fade" data-duration="1000" data-target="references2-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>        
                    </div>

                    <div class="slide-title blue two-line">
                        Limited advances in novel non-transplant therapies for <br />
                        severe aplastic anaemia
                    </div>


                    <div class="content-container">
                
                        <ul>
                            <li><span>The emphasis of most IST trials in severe aplastic anaemia has been in:</span>
                                <ul>
                                    <li><span>Adding different immunosuppressants, including mycophenolate mofetil or sirolimus</span></li>
                                    <li><span>Using more potent lymphotoxic agents such as r-ATG<sup>1</sup></span>
                                        <ul>
                                            <li><span>Neither modification has had a significant impact on the outcomes of response, relapse or development of cytogenetic abnormalities beyond what is expected with h-ATG/CsA alone<sup>1</sup></span></li>
                                        </ul>
                                    </li>
                                </ul>
                            </li>
                            <li><span>Alemtuzumab has been proposed as an effective salvage strategy for relapsed or refractory severe aplastic anaemia, with response rates of 35–58%<sup>2–4</sup></span>
                                <ul>
                                    <li><span>A pilot study by the European Group for Blood and Marrow Transplantation (EMBT) found that post-treatment relapse occurred in 85% of patients<sup>3</sup></span></li>
                                    <li><span>However, retreatment with alemtuzumab produced a partial or complete response in 71% of cases<sup>3</sup></span></li>
                                </ul>
                            </li>
                            <li><span>Despite the lack of new non-transplant treatment options, survival has generally improved over the years, particularly among non-responders<sup>5</sup></span>
                                <ul>
                                    <li><span>Better support during periods of severe neutropenia, particularly the use of empirical antifungal therapy and improved adverse event profiles of newer agents</span></li>
                                    <li><span>Increasingly successful salvage treatment with repeat IST or HSCT</span></li>
                                </ul>
                            </li>
                        </ul>       

                    </div>

                </div>


                <div class="references2-overlay overlay">

                    <header>References</header>
                        
                    <ol>
                        <li class="navigateHref" data-navtarget="media/documents/BolonB-2012-ToxicolPathol-v40p216.pdf"><span>Scheinberg P. <i>Hematology Am Soc Hematol Educ Program</i> 2012;2012:292</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/BolonB-2012-ToxicolPathol-v40p216.pdf"><span>Scheinberg P <i>et al. Blood</i> 2012;119:345</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/BolonB-2012-ToxicolPathol-v40p216.pdf"><span>Risitano AM <i>et al. Br J Haematol</i> 2010;148:791</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/BolonB-2012-ToxicolPathol-v40p216.pdf"><span>Kim H <i>et al. Leuk Res</i> 2009;33:222</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/BolonB-2012-ToxicolPathol-v40p216.pdf"><span>Valdez JM <i>et al. Clin Infect Dis</i> 2011;52:726</span></li>
                    </ol>

                </div>

          
    </div>
    <!-- End of secondary scene 5 -->
    </div>
 </div>